fbpx
Wikipedia

Alnylam Pharmaceuticals

April 27, 2024

Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics[3] for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.[4] In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.[5]

Alnylam Pharmaceuticals, Inc.
Company typePublic
IndustryPharmaceutical
Founded2002; 22 years ago (2002)
HeadquartersCambridge, Massachusetts, U.S.
Key people
Yvonne Greenstreet (CEO)
Revenue US$1.83 billion (2023)
US$1.04 billion (2022)[1]
Number of employees
2,100 (2023)[2]
Websitealnylam.com

History edit

The company is a spin-off from the Max Planck Institute for Biophysical Chemistry.[6] In 2002, Alnylam was founded by scientists Phillip Sharp, Paul Schimmel, David Bartel, Thomas Tuschl, and Phillip Zamore, and by investors Christoph Westphal and John Kennedy Clarke; John Maraganore was the founding CEO.[5][7][8] The company was named after Alnilam, a star in Orion's belt. The spelling was modified to make it unique.[9] In 2003, the firm merged with the German pharmaceutical company, Ribopharma AG. The newly formed company also received $24.6 million in funding from private-equity firms.[10][11] On February 27, 2004, Alnylam Pharmaceuticals filed for an IPO.[7][12] The company raised $26 million and began trading as ALNY on the Nasdaq stock exchange.[13]

In 2005, the company partnered with Medtronic to develop drug-device combinations to treat neurodegenerative disorders,[14] and in 2006 with Biogen Idec to develop treatments of progressive multifocal leukoencephalopathy.[15] In 2007, it entered into a nonexclusive alliance with Hoffmann-La Roche, in which Alnylam received $331 million in exchange for access to its technology platform.[16] and also partnered with Ionis Pharmaceuticals to found the company Regulus Therapeutics, focused on microRNA therapeutics.[17]

In 2009, the company formed alliances with Cubist Pharmaceuticals and Kyowa Hakko Kirin to market a drug targeted at respiratory syncytial virus.[18] In 2010, it expanded its previous collaboration with Medtronic to include the CHDI Foundation in its Huntington's disease focused research.[19] In 2011, it partnered with GlaxoSmithKline to develop RNAi technology enhancing vaccine production.[20][21] The company entered into a 10-year alliance with Monsanto in 2012, to develop biotech solutions for the farming industry by developing natural molecules for crop protection.[22][23][24] In 2012, it formed a partnership with Sanofi Genzyme to develop a treatment for transthyretin-mediated amyloidosis, a hereditary disease in Asia.[25][third-party source needed] In February 2013, it formed a partnership with The Medicines Company to develop a drug to treat a genetic form of high cholesterol.[26]

In July 2013, during a Phase I trial Alnylam demonstrated statistically significant reduction of a protein called transthyretin, or TTR and demonstrated human efficacy with intravenous and subcutaneous modes of administration.[27] In 2014, Sanofi Genzyme acquired a 12 percent stake in Alnylam and increased its rights to several of the company's drugs for $700 million. In a separate transaction Alnylam announced that it had purchased Merck & Co.'s Sirna Therapeutics, for $25 million cash and $150 million in stock.[28][29] In 2015, the company had $41 million in revenue and a market cap of $5.2 billion.[30]

In 2016, the company purchased land in Norton, Massachusetts to build a manufacturing facility.[31][32]

In October 2016 the Phase III clinical trial of the company's lead product, revusiran, was halted due to increased deaths in the drug arm of the trial, and the company said it was terminating development of the compound.[33][34]

In February 2020, Alnylam appointed former Sanofi CEO Olivier Brandicourt to its board of directors.[35] In 2021, it was announced that Maraganore would step down as CEO, to be succeeded by the company's chief operating officer, Yvonne Greenstreet, on January 1, 2022.[36]

In December 2021, Alnylam submitted a clinical trial authorisation (CTA) application to the Medicines and Healthcare Products Regulatory Agency in the United Kingdom to initiate a Phase 1 study of ALN-APP, an investigational RNAi therapeutic targeting amyloid precursor protein (APP) for the treatment of Alzheimer's disease and cerebral amyloid angiopathy.[37]

On December 22, 2021, Novartis announced that the US Food and Drug Administration (FDA) approved Leqvio (inclisiran), a small interfering RNA (siRNA) therapy to lower low-density lipoprotein cholesterol. Leqvio is indicated in the United States as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with clinical atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH) who require additional lowering of LDL-C. The effect of Leqvio on cardiovascular morbidity and mortality is being explored in clinical trials currently underway. Novartis obtained global rights to develop, manufacture and commercialize Leqvio under a license and collaboration agreement with Alnylam Pharmaceuticals.[38]

Alnylam still does not earn money, but writes losses. The losses ("GAAP Operating Loss") from Alnylam were around $650 million in the late 2020. Alnylam expects to achieve net profits financially in 2022 or 2023.[39]

In July 2023, Roche partnered with Alnylam Pharmaceuticals in a deal worth $2.8 billion for the development of a hypertension drug.[40]

Products edit

In 2016, Alnylam Pharmaceuticals had 18 potential treatments[41] in various development stages in genetic medicine, cardiometabolic disease and hepatic infectious disease.

In late 2016, the company's lead candidate in phase III studies was patisiran, a treatment targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR), in patients with the compromised nervous system condition of familial amyloidotic polyneuropathy (FAP).[33] In August 2018, with its commercial name Onpattro, patisiran received the U.S. regulatory approval to treat polyneuropathy in patients with hereditary ATTR amyloidosis.[42]

FDA on patisiran edit

In September 2023, the FDA raised doubts about the efficacy of patisiran for treating cardiomyopathy associated with transthyretin-mediated amyloidosis (ATTR-CM). The FDA's Cardiovascular and Renal Drugs Advisory Committee meeting is scheduled for September 13, 2023. Although the APOLLO-B study met key endpoints, the FDA questioned the clinical significance of the results particularly for patients not on background therapy with tafamidis. The FDA is seeking the committee's input on the clinical meaningfulness and patient populations for patisiran use potentially challenging Pfizer's tafamidis dominance in ATTR-CM treatment. A decision on Alnylam's application is expected by October 8, 2023. Patisiran was previously approved in 2018 for hereditary ATTR amyloidosis polyneuropathy, becoming the first RNA interference therapeutic approved by the FDA.[43]

References edit

  1. ^ "Alnylam Pharmaceuticals Inc. Annual Income Statement". MarketWatch. 12 August 2023.
  2. ^ "Alnylam Pharmaceuticals: Number of Employees 2006-2021". www.macrotrends.net.
  3. ^ "Alnylam Pharmaceuticals Inc (ALNY) Quote - XNAS | Morningstar. Alnylam Pharmaceuticals Inc's Company Profile. Business Description". www.morningstar.com. Retrieved 15 May 2022.
  4. ^ "ALNY | Alnylam Pharmaceuticals Inc. Company Profile & Executives - WSJ". www.wsj.com. Retrieved 15 May 2022.
  5. ^ a b "Most Innovative Growth Companies #100 Alnylam Pharmaceuticals". Forbes. May 2016. Retrieved September 22, 2016.
  6. ^ "50 years of technology transfer for the Max Planck Society". www.mpg.de.
  7. ^ a b Hollmer, Mark (March 8, 2004). "Cambridge Bio-Startup Alnylam Files For IPO". Boston Business Journal. Retrieved September 22, 2016.
  8. ^ "Alnylam S-1". Alnylam via SEC Edgar. February 27, 2004.
  9. ^ Dolgin, Elie (March 9, 2016). "What's in a Biotech Name? How Drug Startups Choose Their Name". STAT. Retrieved September 22, 2016.
  10. ^ Naik, Gautam (July 7, 2003). "Ribopharma, Alnylam Announce Merger". The Wall Street Journal. Retrieved September 22, 2016.
  11. ^ "Alnylam, ribopharma Merge, Notch $24.6 Million in Financing". Boston Business Journal. July 7, 2003. Retrieved September 22, 2016.
  12. ^ "Alnylam Pharmaceuticals, Inc. (ALNY) IPO". Nasdaq. May 28, 2004. Retrieved September 22, 2016.
  13. ^ Fodor, Kate (October 11, 2004). "Biotechs Put Initial Public Offerings On Hold". The Scientist. Retrieved September 22, 2016.
  14. ^ "Medtronic, Alnylam to Seek treatments". Memphis Business Journal. February 9, 2005. Retrieved September 22, 2016.
  15. ^ "Biogen Idec and Alnylam Partner in RNAi Drug Deal". Boston Business Journal. September 21, 2006. Retrieved September 22, 2016.
  16. ^ Greil, Anita (July 10, 2007). "Roche Bets on Gene Research". The Wall Street Journal. Retrieved September 22, 2016.
  17. ^ Hutton, David (June 2011). "Surf's Up For MicroRNAs". Drug Discovery News. Retrieved September 22, 2016.
  18. ^ Roush, Wade (January 9, 2009). "Alnylam, Cubist Will Cooperate on RNAi Drug for Lung Infections". Xconomy. Retrieved September 22, 2016.
  19. ^ Taylor, Nick (November 8, 2010). "Alnylam, Medtronic & CHDI Form RNAi Delivery Collaboration". in-Pharma Technologist. Retrieved September 22, 2016.
  20. ^ Weintraub, Arlene (November 1, 2011). "Alnylam and Glaxo Partner on RNAi for Vaccine Production". Xconomy. Retrieved September 22, 2016.
  21. ^ "GSK Taps Alnylam Tech For Faster Vaccine Production". Fierce Pharma. November 3, 2011. Retrieved September 22, 2016.
  22. ^ Weintraub, Arlene (August 28, 2012). "Alnylam Inks $29M deal With Monsanto For New Bio Tools for Farmers". Xconomy. Retrieved September 22, 2016.
  23. ^ Macron, Doug (September 6, 2012). "Monsanto, Alnylam Form $29M Alliance to Apply RNAi to Agriculture". GenomeWeb. Retrieved September 22, 2016.
  24. ^ "Alnylam and Monsanto Form Strategic Alliance". BusinessWire. August 28, 2012. Retrieved September 22, 2016.
  25. ^ Reidy, Chris (October 22, 2012). "Alnylam, Genzyme Form Alliance". The Boston Globe. Retrieved September 22, 2016.
  26. ^ Pollack, Andrew (February 4, 2013). "Medicines Co. buys Cholesterol Drug Rights". The New York Times. Retrieved September 22, 2016.
  27. ^ Fidler, Ben (July 11, 2013). "Exome: Alnylam Shares Boom on Early Data For Subcutaneous RNA Drug". Xconomy. Retrieved September 4, 2013.
  28. ^ Bennett, Simeon (January 13, 2014). "Sanofi to Pay Alnylam $700 Million for Rare-Disease Drugs". Bloomberg. Retrieved September 22, 2016.
  29. ^ Stanton, Dan (January 13, 2014). "Alnylam Buys Merck's siRNA Tech Biz as Sanofi Inks $700m Alliance". In-Pharma Technologist. Retrieved September 22, 2016.
  30. ^ Seiffert, Don (March 22, 2016). "The 9 fastest-growing biotech firms in the Bay State". Boston Business Journal.
  31. ^ Stanton, Dan (February 17, 2016). "Alnylam Lays Down Plans for Commercial RNAi Manufacturing Plant". In-Pharma Technologist. Retrieved September 22, 2016.
  32. ^ Weisman, Robert (February 11, 2016). "Alnylam Buys Norton Site for $200M Drug Manufacturing Plant". Boston Globe. Retrieved September 22, 2016.
  33. ^ a b Adams, Ben (October 6, 2016). "Alnylam plunges after deaths force it to pull PhIII blockbuster candidate revusiran". FierceBiotech.
  34. ^ "After 18 Deaths in Phase III, Alnylam Halts Revusiran Development". Genetic Engineering and Biotechnology News. October 6, 2016.
  35. ^ "Alnylam Taps Former Sanofi CEO Olivier Brandicourt for Board of Directors". BioSpace. Retrieved February 28, 2020.
  36. ^ Jonathan Saltzman (November 28, 2021). "Alnylam is getting a rare kind of leader". The Boston Globe.
  37. ^ "Alnylam Submits CTA Application for ALN-APP, an Investigational RNAi Therapeutic for the Treatment of Alzheimer's Disease and Cerebral Amyloid Angiopathy". www.businesswire.com. December 22, 2021. Retrieved December 30, 2021.
  38. ^ "FDA approves Novartis Leqvio (inclisiran)". Novartis. December 22, 2021.
  39. ^ "Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Peri". Investor Relations | Alnylam Pharmaceuticals, Inc. Retrieved 2022-08-26.
  40. ^ "Roche Signs $2.8 Billion Alnylam Deal for Hypertension Drug". Bloomberg.com. 2023-07-24. Retrieved 2023-07-25.
  41. ^ "Alnylam Pharmaceuticals Inc". BioCentury. Retrieved September 22, 2016.
  42. ^ Tamara Mathias (10 August 2018). "Alnylam's gene silencing drug wins FDA approval". Reuters. Retrieved 20 May 2022.
  43. ^ Lynch, Connor. "FDA Questions Efficacy of Alnylam's Drug in ATTR-CM Ahead of Adcomm Meeting".

External links edit

  • Official website
  • Business data for Alnylam Pharmaceuticals, Inc.:
    • Bloomberg
    • Google
    • Reuters
    • SEC filings
    • Yahoo!
  • Alnylam on ClinicalTrials.gov

April 27, 2024
alnylam, pharmaceuticals, american, biopharmaceutical, company, focused, discovery, development, commercialization, interference, rnai, therapeutics, genetically, defined, diseases, company, founded, 2002, headquartered, cambridge, massachusetts, 2016, forbes,. Alnylam Pharmaceuticals Inc is an American biopharmaceutical company focused on the discovery development and commercialization of RNA interference RNAi therapeutics 3 for genetically defined diseases The company was founded in 2002 and is headquartered in Cambridge Massachusetts 4 In 2016 Forbes included the company on its 100 Most Innovative Growth Companies list 5 Alnylam Pharmaceuticals Inc Company typePublicTraded asNasdaq ALNYRussell 1000 componentIndustryPharmaceuticalFounded2002 22 years ago 2002 HeadquartersCambridge Massachusetts U S Key peopleYvonne Greenstreet CEO RevenueUS 1 83 billion 2023 US 1 04 billion 2022 1 Number of employees2 100 2023 2 Websitealnylam wbr com Contents 1 History 2 Products 2 1 FDA on patisiran 3 References 4 External linksHistory editThe company is a spin off from the Max Planck Institute for Biophysical Chemistry 6 In 2002 Alnylam was founded by scientists Phillip Sharp Paul Schimmel David Bartel Thomas Tuschl and Phillip Zamore and by investors Christoph Westphal and John Kennedy Clarke John Maraganore was the founding CEO 5 7 8 The company was named after Alnilam a star in Orion s belt The spelling was modified to make it unique 9 In 2003 the firm merged with the German pharmaceutical company Ribopharma AG The newly formed company also received 24 6 million in funding from private equity firms 10 11 On February 27 2004 Alnylam Pharmaceuticals filed for an IPO 7 12 The company raised 26 million and began trading as ALNY on the Nasdaq stock exchange 13 In 2005 the company partnered with Medtronic to develop drug device combinations to treat neurodegenerative disorders 14 and in 2006 with Biogen Idec to develop treatments of progressive multifocal leukoencephalopathy 15 In 2007 it entered into a nonexclusive alliance with Hoffmann La Roche in which Alnylam received 331 million in exchange for access to its technology platform 16 and also partnered with Ionis Pharmaceuticals to found the company Regulus Therapeutics focused on microRNA therapeutics 17 In 2009 the company formed alliances with Cubist Pharmaceuticals and Kyowa Hakko Kirin to market a drug targeted at respiratory syncytial virus 18 In 2010 it expanded its previous collaboration with Medtronic to include the CHDI Foundation in its Huntington s disease focused research 19 In 2011 it partnered with GlaxoSmithKline to develop RNAi technology enhancing vaccine production 20 21 The company entered into a 10 year alliance with Monsanto in 2012 to develop biotech solutions for the farming industry by developing natural molecules for crop protection 22 23 24 In 2012 it formed a partnership with Sanofi Genzyme to develop a treatment for transthyretin mediated amyloidosis a hereditary disease in Asia 25 third party source needed In February 2013 it formed a partnership with The Medicines Company to develop a drug to treat a genetic form of high cholesterol 26 In July 2013 during a Phase I trial Alnylam demonstrated statistically significant reduction of a protein called transthyretin or TTR and demonstrated human efficacy with intravenous and subcutaneous modes of administration 27 In 2014 Sanofi Genzyme acquired a 12 percent stake in Alnylam and increased its rights to several of the company s drugs for 700 million In a separate transaction Alnylam announced that it had purchased Merck amp Co s Sirna Therapeutics for 25 million cash and 150 million in stock 28 29 In 2015 the company had 41 million in revenue and a market cap of 5 2 billion 30 In 2016 the company purchased land in Norton Massachusetts to build a manufacturing facility 31 32 In October 2016 the Phase III clinical trial of the company s lead product revusiran was halted due to increased deaths in the drug arm of the trial and the company said it was terminating development of the compound 33 34 In February 2020 Alnylam appointed former Sanofi CEO Olivier Brandicourt to its board of directors 35 In 2021 it was announced that Maraganore would step down as CEO to be succeeded by the company s chief operating officer Yvonne Greenstreet on January 1 2022 36 In December 2021 Alnylam submitted a clinical trial authorisation CTA application to the Medicines and Healthcare Products Regulatory Agency in the United Kingdom to initiate a Phase 1 study of ALN APP an investigational RNAi therapeutic targeting amyloid precursor protein APP for the treatment of Alzheimer s disease and cerebral amyloid angiopathy 37 On December 22 2021 Novartis announced that the US Food and Drug Administration FDA approved Leqvio inclisiran a small interfering RNA siRNA therapy to lower low density lipoprotein cholesterol Leqvio is indicated in the United States as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with clinical atherosclerotic cardiovascular disease ASCVD or heterozygous familial hypercholesterolemia HeFH who require additional lowering of LDL C The effect of Leqvio on cardiovascular morbidity and mortality is being explored in clinical trials currently underway Novartis obtained global rights to develop manufacture and commercialize Leqvio under a license and collaboration agreement with Alnylam Pharmaceuticals 38 Alnylam still does not earn money but writes losses The losses GAAP Operating Loss from Alnylam were around 650 million in the late 2020 Alnylam expects to achieve net profits financially in 2022 or 2023 39 In July 2023 Roche partnered with Alnylam Pharmaceuticals in a deal worth 2 8 billion for the development of a hypertension drug 40 Products editIn 2016 Alnylam Pharmaceuticals had 18 potential treatments 41 in various development stages in genetic medicine cardiometabolic disease and hepatic infectious disease In late 2016 the company s lead candidate in phase III studies was patisiran a treatment targeting transthyretin TTR for the treatment of TTR mediated amyloidosis ATTR in patients with the compromised nervous system condition of familial amyloidotic polyneuropathy FAP 33 In August 2018 with its commercial name Onpattro patisiran received the U S regulatory approval to treat polyneuropathy in patients with hereditary ATTR amyloidosis 42 FDA on patisiran edit In September 2023 the FDA raised doubts about the efficacy of patisiran for treating cardiomyopathy associated with transthyretin mediated amyloidosis ATTR CM The FDA s Cardiovascular and Renal Drugs Advisory Committee meeting is scheduled for September 13 2023 Although the APOLLO B study met key endpoints the FDA questioned the clinical significance of the results particularly for patients not on background therapy with tafamidis The FDA is seeking the committee s input on the clinical meaningfulness and patient populations for patisiran use potentially challenging Pfizer s tafamidis dominance in ATTR CM treatment A decision on Alnylam s application is expected by October 8 2023 Patisiran was previously approved in 2018 for hereditary ATTR amyloidosis polyneuropathy becoming the first RNA interference therapeutic approved by the FDA 43 References edit Alnylam Pharmaceuticals Inc Annual Income Statement MarketWatch 12 August 2023 Alnylam Pharmaceuticals Number of Employees 2006 2021 www macrotrends net Alnylam Pharmaceuticals Inc ALNY Quote XNAS Morningstar Alnylam Pharmaceuticals Inc s Company Profile Business Description www morningstar com Retrieved 15 May 2022 ALNY Alnylam Pharmaceuticals Inc Company Profile amp Executives WSJ www wsj com Retrieved 15 May 2022 a b Most Innovative Growth Companies 100 Alnylam Pharmaceuticals Forbes May 2016 Retrieved September 22 2016 50 years of technology transfer for the Max Planck Society www mpg de a b Hollmer Mark March 8 2004 Cambridge Bio Startup Alnylam Files For IPO Boston Business Journal Retrieved September 22 2016 Alnylam S 1 Alnylam via SEC Edgar February 27 2004 Dolgin Elie March 9 2016 What s in a Biotech Name How Drug Startups Choose Their Name STAT Retrieved September 22 2016 Naik Gautam July 7 2003 Ribopharma Alnylam Announce Merger The Wall Street Journal Retrieved September 22 2016 Alnylam ribopharma Merge Notch 24 6 Million in Financing Boston Business Journal July 7 2003 Retrieved September 22 2016 Alnylam Pharmaceuticals Inc ALNY IPO Nasdaq May 28 2004 Retrieved September 22 2016 Fodor Kate October 11 2004 Biotechs Put Initial Public Offerings On Hold The Scientist Retrieved September 22 2016 Medtronic Alnylam to Seek treatments Memphis Business Journal February 9 2005 Retrieved September 22 2016 Biogen Idec and Alnylam Partner in RNAi Drug Deal Boston Business Journal September 21 2006 Retrieved September 22 2016 Greil Anita July 10 2007 Roche Bets on Gene Research The Wall Street Journal Retrieved September 22 2016 Hutton David June 2011 Surf s Up For MicroRNAs Drug Discovery News Retrieved September 22 2016 Roush Wade January 9 2009 Alnylam Cubist Will Cooperate on RNAi Drug for Lung Infections Xconomy Retrieved September 22 2016 Taylor Nick November 8 2010 Alnylam Medtronic amp CHDI Form RNAi Delivery Collaboration in Pharma Technologist Retrieved September 22 2016 Weintraub Arlene November 1 2011 Alnylam and Glaxo Partner on RNAi for Vaccine Production Xconomy Retrieved September 22 2016 GSK Taps Alnylam Tech For Faster Vaccine Production Fierce Pharma November 3 2011 Retrieved September 22 2016 Weintraub Arlene August 28 2012 Alnylam Inks 29M deal With Monsanto For New Bio Tools for Farmers Xconomy Retrieved September 22 2016 Macron Doug September 6 2012 Monsanto Alnylam Form 29M Alliance to Apply RNAi to Agriculture GenomeWeb Retrieved September 22 2016 Alnylam and Monsanto Form Strategic Alliance BusinessWire August 28 2012 Retrieved September 22 2016 Reidy Chris October 22 2012 Alnylam Genzyme Form Alliance The Boston Globe Retrieved September 22 2016 Pollack Andrew February 4 2013 Medicines Co buys Cholesterol Drug Rights The New York Times Retrieved September 22 2016 Fidler Ben July 11 2013 Exome Alnylam Shares Boom on Early Data For Subcutaneous RNA Drug Xconomy Retrieved September 4 2013 Bennett Simeon January 13 2014 Sanofi to Pay Alnylam 700 Million for Rare Disease Drugs Bloomberg Retrieved September 22 2016 Stanton Dan January 13 2014 Alnylam Buys Merck s siRNA Tech Biz as Sanofi Inks 700m Alliance In Pharma Technologist Retrieved September 22 2016 Seiffert Don March 22 2016 The 9 fastest growing biotech firms in the Bay State Boston Business Journal Stanton Dan February 17 2016 Alnylam Lays Down Plans for Commercial RNAi Manufacturing Plant In Pharma Technologist Retrieved September 22 2016 Weisman Robert February 11 2016 Alnylam Buys Norton Site for 200M Drug Manufacturing Plant Boston Globe Retrieved September 22 2016 a b Adams Ben October 6 2016 Alnylam plunges after deaths force it to pull PhIII blockbuster candidate revusiran FierceBiotech After 18 Deaths in Phase III Alnylam Halts Revusiran Development Genetic Engineering and Biotechnology News October 6 2016 Alnylam Taps Former Sanofi CEO Olivier Brandicourt for Board of Directors BioSpace Retrieved February 28 2020 Jonathan Saltzman November 28 2021 Alnylam is getting a rare kind of leader The Boston Globe Alnylam Submits CTA Application for ALN APP an Investigational RNAi Therapeutic for the Treatment of Alzheimer s Disease and Cerebral Amyloid Angiopathy www businesswire com December 22 2021 Retrieved December 30 2021 FDA approves Novartis Leqvio inclisiran Novartis December 22 2021 Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Peri Investor Relations Alnylam Pharmaceuticals Inc Retrieved 2022 08 26 Roche Signs 2 8 Billion Alnylam Deal for Hypertension Drug Bloomberg com 2023 07 24 Retrieved 2023 07 25 Alnylam Pharmaceuticals Inc BioCentury Retrieved September 22 2016 Tamara Mathias 10 August 2018 Alnylam s gene silencing drug wins FDA approval Reuters Retrieved 20 May 2022 Lynch Connor FDA Questions Efficacy of Alnylam s Drug in ATTR CM Ahead of Adcomm Meeting External links editOfficial website Business data for Alnylam Pharmaceuticals Inc BloombergGoogleReutersSEC filingsYahoo Alnylam on ClinicalTrials gov Retrieved from https en wikipedia org w index php title Alnylam Pharmaceuticals amp oldid 1220516340, wikipedia, wiki, book, books, library,

article

, read, download, free, free download, mp3, video, mp4, 3gp, jpg, jpeg, gif, png, picture, music, song, movie, book, game, games.